GlassScriptPhysician profile
Maaz Jalil
NPI 1376039529
$17,104.38
in general payments reported to CMS, 2019-2025
35 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $87.30 · 2021: $319 · 2022: $1,154 · 2023: $1,971 · 2024: $2,898 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,122 · Consulting Fee: $6,266 · Travel and Lodging: $815 · Education: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,121.58 |
| Consulting Fee | $6,266.00 |
| Travel and Lodging | $815.13 |
| Education | $341.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $9,036.09 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,496.71 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,142.66 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $711.48 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $493.66 | 2021-2025 | Hyqvia, Cuvitru, Takhzyro |
| Grifols USA, LLC | $399.59 | 2021-2025 | Xembify, Gamunex-C |
| Csl Behring | $383.34 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Genentech USA, INC. | $368.46 | 2020-2025 | Xolair |
| Optinose US, INC. | $293.83 | 2023-2025 | |
| Blueprint Medicines Corporation | $275.23 | 2022-2024 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $260.78 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $257.97 | 2023-2025 | |
| Amgen INC. | $254.81 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $249.01 | 2022-2025 | |
| Pfizer INC. | $229.67 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $228.03 | 2021-2024 | Auvi-Q |
| Abbvie INC. | $188.59 | 2022-2025 | |
| Pharming Healthcare, INC. | $150.69 | 2023-2025 | Ruconest |
| Hikma Pharmaceuticals USA | $123.25 | 2023-2025 | Ryaltris |
| Biocryst US Sales Co., LLC | $104.69 | 2022-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $71.90 | 2021-2023 | Airduo Digihaler |
| Covis Pharma Gmbh | $38.31 | 2022 | |
| Ionis Pharmaceuticals, INC. | $35.28 | 2025 | Dawnzera |
| Horizon Therapeutics Plc | $34.06 | 2021 | |
| Cycle Pharmaceuticals INC | $28.25 | 2025 | Sajazir |
| Inspire Medical Systems, INC. | $24.83 | 2023 | Inspire |
| Octapharma USA, INC. | $19.35 | 2022 | |
| Phadia US INC. | $18.52 | 2023 | Immunocap |
| Lilly USA, LLC | $18.21 | 2025 | Ebglyss, Taltz |
| Organon LLC | $17.79 | 2025 | |
| Azurity Pharmaceuticals, INC. | $17.75 | 2025 | Alvesco |
| Greer Laboratories, INC. | $17.00 | 2025 | Oralair |
| Merck Sharp & Dohme LLC | $14.36 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2021 | |
| Leo Pharma INC. | $13.13 | 2024 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maaz Jalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.